

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

WSTR-0017K

Inventors:

Gerhard and Otvos

Serial No.:

Not yet assigned

Filing Date:

Herewith

Examiner:

Not yet assigned

Group Art Unit:

Not yet assigned

Title:

Composition and Method for

Preventing or Treating a Virus

Infection

"Express Mail" Label No. **EV626224758US**Date of Deposit <u>July 8, 2005</u>

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313

Mail Stop PCT Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- (XX) In accordance with §1.97(b), since this Information

 Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information
 Disclosure Statement is being filed after the period
 set forth in §1.97(b) above but before the mailing date
 of either a Final Action under §1.113 or a Notice of
 Allowance under §1.311, therefore:
 - () Certification in Accordance with §1.97(e) is attached hereto; or
 - () The fee of $$\underline{180.00}$$ as set forth in \$1.17(p) is attached.
- () In accordance with §1.97(d), this Information
 Disclosure Statement is being filed after the mailing
 date of either a Final Action under §1.113 or a Notice
 of Allowance under §1.311 but before the payment of the
 Issue Fee, therefore included are: Certification in
 Accordance with §1.97(e); Petition Requesting
 Consideration of the Information Disclosure Statement;
 and the fee of \$130.00 as set forth in §1.17(I)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

10/541771

JC20 Rec'd PCT/P10 28 JUL 2005

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _______, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

- () The relevance of the listed references in a foreign language is as stated in the specification at pages @@.
- (XX) All listed references are in the English language.

Respectfully submitted,

Janess Jecar

Jane Massey Licata Registration No. 32,257

Date: July 8, 2005

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515

Docket No. Form PTO-1449 Modified WSTR-0017K List of Patents and Publications Applicant Cited by Applicant Gerhard and Otvos (Use several sheets if necessary) Filing Date Group U.S. Department of Commerce Herewith Not yet assigned OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Kragol et al.: Orthogonal Solid-Phase Synthesis of Tetramannosylated Peptide Constructs Carrying Three Independent Branched Epitopes, Tetrahedron 57 (2001) 957-966 AB Kragol et al.: Synthesis of a Disulfide-Linked Octameric Peptide Construct Carrying Three Different Antigenic Determinants, Bioorganic & Medicinal Chemistry Letters 11 (2001) 1417-1420 Mozdzanowska et al.: Induction of Influenza Type A Virus-Specific Resistance by Immunization of Mice With a Synthetic Multiple Antigenic Peptide Vaccine That Contains Ectodomains of Matrix Protein 2, Vaccine 21 (2003) 2616-2626 Neirynck et al.: A Universal Influenza A Vaccine Based on the Extracellular AD Domain of the M2 Protein, Nature Medicine, Volume 5, Number 10, October 1999 EXAMINER DATE CONSIDERED